Skip to main content
. 2015 Apr 28;54(10):1043–1055. doi: 10.1007/s40262-015-0271-5

Fig. 5.

Fig. 5

Concentration–time profiles (mean ± standard deviation) for the sum of enzalutamide plus N-desmethyl enzalutamide after a single oral dose of enzalutamide 160 mg in male subjects: a subjects with mild hepatic impairment (Child–Pugh Class A; n = 8) and the age- and BMI-matched control subjects with normal hepatic function (n = 8); b subjects with moderate hepatic impairment (Child–Pugh Class B; n = 6) and the age- and BMI-matched control subjects with normal hepatic function (n = 6). BMI body mass index